

Melphalan flufenamide (melflufen) and Dexamethasone Re-induction in Daratumumab-refractory Multiple Myeloma as an Adjunct to Continued Daratumumab (MERMAID),
EUDRACT number 2020-004349-35
Note of early termination

Due to the results of the phase 3 OCEAN study, where melflufen-dexamethasone treatment resulted in worse overall survival than pomalidomide-dexamethasone treatment, Oncopeptides, the company that owns melflufen, has decided to withdraw melflufen from the market in USA and terminate all trials with melflufen, including support for investigator initiated studies. Due to this the MERMAID study terminates early. The study was initiated at Vejle Hospital, but no patients were screened or included.

Agoston Gyula Szabo 12. NOV. 2021



Primary Investigator